Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Multiple Myeloma: Revlimid in the European Market
A Survey of 51 European Oncologists
December 2007
Deliverable: Survey in PowerPoint with key kindings.
Study Description:
|
Respondent Type |
Physicians |
|
Specialties Covered |
Oncology |
|
Region |
Europe |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website § Approximately 20 minutes duration § 50 total respondents § Fielded online from December 6, 2007 to December 17, 2007 |
Objectives:
To understand current practices and trends regarding the use of newly approved agents in patients with multiple myeloma (MM) and the impact of newly approved Revlimid in this market. Additionally to:
§ Determine current practice patterns in MM
§ Quantify usage of newly indicated agents in MM patients
§ Predict the barriers to entry of new therapies into a more price sensitive European market
§ Determine the effectiveness of Celgene’s commercial organization for launching Revlimid
Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Celgene |
CELG |
Revlimid, Thalidomid, Alkeran / melphalan |
|
Millennium |
MLNM |
Velcade |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria
|
§ 51 Oncologists: Germany – 25, France – 21 & Austria – 5 § At least 2 years in practice post-training § Spend at least 75% time in patient care § Manage at least 30 multiple myeloma patients § Have enrolled at most 75% of MM patients in clinical trials § Have prescribed Revlimid-containing regimen to at least 5 patients |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |